The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Human APOA-I, After Acute Myocardial Infarction - The APOA-I Event Reduction in Ischemic Syndromes I (AEGIS-I) Trial
Publication
, Conference
Gibson, CM; Korjian, S; Tricoci, P; Daaboul, Y; Alexander, JH; Steg, PG; Lincoff, AM; Kastelein, JJ; Mehran, R; D'Andrea, D; Merkely, B ...
Published in: CIRCULATION
December 20, 2016
Duke Scholars
Published In
CIRCULATION
EISSN
1524-4539
ISSN
0009-7322
Publication Date
December 20, 2016
Volume
134
Issue
25
Start / End Page
E706 / E706
Location
New Orleans, LA
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Conference Name
Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Gibson, C. M., Korjian, S., Tricoci, P., Daaboul, Y., Alexander, J. H., Steg, P. G., … Harrington, R. A. (2016). The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Human APOA-I, After Acute Myocardial Infarction - The APOA-I Event Reduction in Ischemic Syndromes I (AEGIS-I) Trial. In CIRCULATION (Vol. 134, pp. E706–E706). New Orleans, LA: LIPPINCOTT WILLIAMS & WILKINS.
Gibson, C Michael, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, John H. Alexander, Philippe G. Steg, A. M. Lincoff, et al. “The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Human APOA-I, After Acute Myocardial Infarction - The APOA-I Event Reduction in Ischemic Syndromes I (AEGIS-I) Trial.” In CIRCULATION, 134:E706–E706. LIPPINCOTT WILLIAMS & WILKINS, 2016.
Gibson CM, Korjian S, Tricoci P, Daaboul Y, Alexander JH, Steg PG, et al. The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Human APOA-I, After Acute Myocardial Infarction - The APOA-I Event Reduction in Ischemic Syndromes I (AEGIS-I) Trial. In: CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2016. p. E706–E706.
Gibson, C. Michael, et al. “The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Human APOA-I, After Acute Myocardial Infarction - The APOA-I Event Reduction in Ischemic Syndromes I (AEGIS-I) Trial.” CIRCULATION, vol. 134, no. 25, LIPPINCOTT WILLIAMS & WILKINS, 2016, pp. E706–E706.
Gibson CM, Korjian S, Tricoci P, Daaboul Y, Alexander JH, Steg PG, Lincoff AM, Kastelein JJ, Mehran R, D’Andrea D, Merkely B, Zarebinski M, Ophius TO, Harrington RA. The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Human APOA-I, After Acute Myocardial Infarction - The APOA-I Event Reduction in Ischemic Syndromes I (AEGIS-I) Trial. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2016. p. E706–E706.
Published In
CIRCULATION
EISSN
1524-4539
ISSN
0009-7322
Publication Date
December 20, 2016
Volume
134
Issue
25
Start / End Page
E706 / E706
Location
New Orleans, LA
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Conference Name
Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology